Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 16/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19837854 | 1.00 | ADORA3 (0.69) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL19843955 | 0.87 | ADORA3 (0.70) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL14408092 | 0.87 | ADORA3 (0.70) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL19837846 | 0.87 | ADORA3 (0.70) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL18172268 | 0.86 | ADORA3 (0.74) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL19837865 | 0.86 | ADORA3 (0.69) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL17234120 | 0.85 | ADORA3 (0.77) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL12240151 | 0.84 | ADORA3 (0.66) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL23884966 | 0.83 | ADORA3 (0.74) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL10015793 | 0.83 | ADORA3 (0.74) | ADORA3ADORA1ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | UTI LIMITED PARTNERSHIP (CA) | 2018-02-08 | — | — | US | disclosed |
| WO-2016168911-A1 | NUCLEOSIDE-BASED ANTI-BACTERIAL AND ANTI-PROTOZOAN DRUGS | UTI LIMITED PARTNERSHIP (CA) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | PNP, NUDT1, SLC29A1 | ADORA3 78/4885ADORA1 73/4885ADORA2B 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.